Company Filing History:
Years Active: 2017
Title: Richard Labrecque: Innovator in Antiandrogen Research
Introduction
Richard Labrecque is a notable inventor based in St-Nicolas, Canada. He has made significant contributions to the field of pharmaceuticals, particularly in the development of non-steroidal antiandrogens and selective androgen receptor modulators. His work aims to address various androgen-dependent diseases, showcasing his commitment to advancing medical science.
Latest Patents
Richard Labrecque holds a patent for "Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety." This patent includes compounds that are utilized to treat or reduce the likelihood of acquiring androgen-dependent diseases such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia, male baldness, muscle atrophy and weakness, sarcopenia, male hypogonadism, erectile dysfunction, female sexual dysfunction, and osteoporosis. These compounds can be formulated with pharmaceutically acceptable diluents or carriers and can be made into various pharmaceutical dosage forms. Additionally, combinations with other active pharmaceutical agents are disclosed in his patent.
Career Highlights
Richard Labrecque is associated with Endorecherche, Inc., where he continues to innovate in the pharmaceutical sector. His work has led to advancements in treatments that significantly impact patients' lives. His dedication to research and development has established him as a key figure in his field.
Collaborations
Richard has collaborated with esteemed colleagues such as Fernand Labrie and Shankar Mohan Singh. These partnerships have fostered an environment of innovation and have contributed to the success of their collective research efforts.
Conclusion
Richard Labrecque's contributions to the field of antiandrogen research highlight his role as a significant inventor in the pharmaceutical industry. His innovative work continues to pave the way for new treatments that address critical health issues.